(Q33732581)

English

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

phase II clinical trial

0 references

7

object named as

Mark J Ratain

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Daniel J. Sargent

object named as

Daniel Sargent

3

1 reference

ORCID Public Data File 2021

author name string

Lesley Seymour

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

S Percy Ivy

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

David Spriggs

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Laurence Baker

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Larry Rubinstein

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Michael Le Blanc

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

David Stewart

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

John Crowley

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Susan Groshen

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jeffrey S Humphrey

12

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Pamela West

13

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Donald Berry

14

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

9 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1764-1769

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

GCP data quality for early clinical development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Issues in using progression-free survival when evaluating oncology products

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Considerations for the use of imaging tools for phase II treatment trials in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Randomized phase II designs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Effective incorporation of biomarkers into phase II trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Alternate endpoints for screening phase II studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Novel designs and end points for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Adaptive clinical trials: progress and challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Proposal for the use of progression-free survival in unblinded randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Design issues of randomized phase II trials and a proposal for phase II screening trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Randomized phase II designs in cancer clinical trials: current status and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

14 July 2018

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2840069

30 October 2018

Phase II trials in journal of clinical oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized discontinuation design: application to cytostatic antineoplastic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II stopping rules that employ response rates and early progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/20215557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-09-3287

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33732581&oldid=1958996927"